Impact Factor 3.707 | CiteScore 5.1
More on impact ›


Front. Neurosci., 01 May 2013 |

Erratum: The promise of neuroprotective agents in Parkinson's disease

Stacey E. Seidl1 and Judith A. Potashkin2*
  • 1The Department of Biological Sciences, DePaul University, Chicago, IL, USA
  • 2The Cellular and Molecular Pharmacology Department, The Chicago Medical School, RFUMS, North Chicago, IL, USA

A commentary on
The promise of neuroprotective agents in Parkinson's disease

by Seidl, S. E., and Potashkin, J. A., (2011). Front. Neurol. 2:68. doi: 10.3389/fneur.2011.00068

After our article was published online, it was brought to our attention that in Table 1 we incorrectly stated the findings from a study testing the safety of Isradipine (Simuni et al., 2010). We have thus changed the text in the table to reflect the results that Isradipine has been shown to be safe and well-tolerated in PD patients.


Table 1. Neuroprotective Agents in PD models.


Simuni T., Borushko E., Avram M. J., Miskevics S., Martel A., Zadikoff C., et al. (2010). Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov. Disord. 25, 2863–2866.

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

Citation: Seidl SE and Potashkin JA (2013) Erratum: The promise of neuroprotective agents in Parkinson's disease. Front. Neurosci. 7:69. doi: 10.3389/fnins. 2013.00069

Received: 27 March 2013; Accepted: 15 April 2013;
Published online: 01 May 2013.

Edited by:

Nick Andrews, Children's Hospital Boston, USA

Reviewed by:

Anders Haunso, Merck, UK
Zubair Ahmed, University of Birmingham, UK

Copyright © 2013 Seidl and Potashkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.